Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Appendix A Public Meeting Agendas FIRST PUBLIC MEETING January 28, 2019 National Academy of Sciences Building 2101 Constitution Avenue, NW Washington, DC 20001 Board Room 1:00â1:10 p.m. ET Welcome and introductions; Conduct of the Open Session Savitz, Ph.D., Committee Chair David 1:10â1:50 p.m. Charge to the Committee Peter R. Rumm, M.D., M.P.H., Director, Pre-9/11 Era Environmental Health Program, Department of Veterans Affairs, with Dr. R. Loren Erickson, Chief Consultant, Post Deployment Health 1:50â2:20 p.m. Overview of Antimalarials Use Policy and Monitoring in Service Members COL Andrew Wiesen, M.D., M.P.H., Director, Preventive Medicine, Health Readiness Policy and Oversight, Office of the Assistant Secretary of Defense (Health Affairs) 379
380 LONG-TERM HEALTH EFFECTS OF ANTIMALARIAL DRUGS 2:20â2:50 p.m. Drug Administration Adverse Events Report- Food and ing System Kelly Yoojung Cao, Pharm.D., Team Leader, Division of Pharmacovigilance II, Food and Drug Administration 2:50â3:30 p.m. Centers for Disease Control and Prevention Monitoring of Malaria and Research Related to Antimalarials Use Kathrine Tan, M.D., M.P.H., Chief, Domestic Response Unit, Malaria Branch, Centers for Disease Control and Prevention 3:30â3:50 p.m. Identifying and Evaluating Sources of Evidence of Quinism: A Novel Disease Affecting U.S. VeteransÂ M.P.H., Dr.P.H., Executive Remington Nevin, M.D., Director, The Quinism Foundation 3:50â4:20 p.m.1 Public Comments Limited to 3 minutes per individual/organization 4:20 p.m. OPEN SESSION ENDS 1â To be extended if needed to accommodate those wishing to make a public statement.
APPENDIX A 381 SECOND PUBLIC MEETING AGENDA March 27, 2019 OPEN SESSION Keck Building 500 Fifth Street, NW, Washington, DC Keck Room 105 9:30â9:35 a.m. ET elcome and Introductions; Conduct of the Open Ses- W sion David Savitz, Ph.D., Committee Chair 9:35â10:05 a.m. Overview of Antimalarials Use Policy and Monitoring in Peace Corps Volunteers Kyle Petersen, D.O, F.I.D.S.A., F.A.C.P., Director of Epidemiology, Peace Corps 10:05â10:25 a.m. AntimalarialsâUse Policy and Monitoring in Deployed Employees of Department of State Kim Ottwell, M.D., Clinical Director of Clinical Services 10:25â11:25 a.m. Neurotoxic Mechanisms of Antimalarials Thomas Brewer, M.D., University of Washington, and Principle, Global Enterics, LLC 11:25â11:50 a.m. Public Comments Limited to 3 minutes per individual/organization 11:50 a.m. OPEN SESSION ENDS